Case TS-8908489513 Nov 2026Health

Health

“Because if you have the gene mutation M T H F R, which is the most popular gene mutation in the world, you cannot process folic acid." (claim text as submitted: "Folic acid cannot be processed by people with the MTHFR gene mutation.")”

Plain restatementPeople who carry a common variant in the MTHFR gene are unable to metabolise folic acid, and should therefore take methylfolate instead of folic acid, including during pregnancy.

FalseConfidence High
What this verdict means →

General information only - not medical advice.

This claim is false as stated. The US Centers for Disease Control and Prevention says directly that people with an MTHFR gene variant can process all forms of folate, including folic acid. Carrying the most common variant does slightly reduce how efficiently the body handles folate, with average blood folate about 16 percent lower in people with two copies, but that is a difference in efficiency, not an inability. The variant also affects folate from food in the same way, so it is not a folic acid specific problem. Folic acid is the only form of folate shown in trials to prevent neural tube defects, with a landmark randomised trial showing a 72 percent reduction in recurrence, and methylfolate has no equivalent evidence for that outcome. The linked suggestion that folic acid worsens ADHD has been reviewed before and no supporting evidence was found. It is true that folic acid is synthetic and was first made in the 1940s, but being lab made is not an argument against a nutrient that has been tested in randomised trials. Anyone pregnant or planning pregnancy should take questions about which prenatal supplement to use to their own healthcare provider rather than changing it based on a video. This is general information only and not medical advice.

The drift / as claimed vs as evidenced

[drifted from the evidence:] Because if you have the gene mutation M T H F R, which is the most popular gene mutation in the [drifted from the evidence:] world, you cannot process folic acid." [drifted from the evidence:] (claim text as submitted: "Folic acid [drifted from the evidence:] cannot be processed by people with the MTHFR gene mutation.")


[added by the neutral restatement:] People who carry a common variant in the [added by the neutral restatement:] MTHFR gene are unable to metabolise folic acid, [added by the neutral restatement:] and should therefore take methylfolate instead of folic acid, [added by the neutral restatement:] including during pregnancy.

Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.

The trace / claim to source

▲ Exaggeration
A real finding gets inflated: stronger, bigger, faster, or more certain than the evidence supports.
⌿ Omitted qualifier
A load-bearing condition from the source quietly disappears from the claim.
→ Causal overreach
A correlation or association presented as cause and effect.
Secondary sourceofficial body statements
CDC genetics experts Q&A via Medscape, "MTHFR and Birth Defects: Does Type of Folate Matter?"
Secondary sourcegovernment health library
MedlinePlus (NIH/NLM), "MTHFR Gene Test"
Secondary sourceclinical institution
Cleveland Clinic, "MTHFR Gene Variant"
Secondary sourceexpert-reviewed fact check
Science Feedback review of an earlier Gary Brecka folic acid claim
Secondary sourceacademic institution
Linus Pauling Institute, Micronutrient Information Center, Folate
Primary sourceofficial body
CDC, "MTHFR Gene Variant and Folic Acid Facts"
Primary sourcepeer-reviewed
Tsang et al., systematic review and meta-analysis of MTHFR 677C>T and blood folate concentrations, American Journal of Clinical Nutrition
Primary sourcepeer-reviewed
MRC Vitamin Study Research Group (1991), randomised controlled trial, The Lancet
● Primary source found
What is true
  • Folic acid is the synthetic, oxidised form of vitamin B9 used in supplements and fortification, and it is chemically distinct from the folates found in leafy greens, legumes and citrus. The post's caption states this correctly.
  • Folic acid was first synthesised in the 1940s. Folate and folic acid were first synthesized in 1945.
  • MTHFR variants are genuinely common. The CDC confirms that more people in the US carry one or two copies of C677T than do not.
  • The C677T variant does measurably reduce enzyme efficiency and is associated with somewhat lower blood folate. The CDC puts the average difference for TT individuals at about 16 percent lower blood folate.
  • Methylfolate is a bioactive form that bypasses the MTHFR step. Methyltetrahydrofolate is the MTHFR product and does not require DHFR reduction to enter one-carbon metabolism.
  • The caption's own safety language, that folic acid before and during early pregnancy is recommended by major health organisations and that people should consult a provider, is accurate and contradicts the video's spoken advice.
What is misleading
  • Exaggeration / binary framing: the claim says people with MTHFR "cannot process folic acid." The CDC states people with an MTHFR gene variant can process all types of folate, including folic acid. Reduced enzyme efficiency has been converted into total inability. This is the central distortion.
  • Omitted qualifier: the claim does not distinguish heterozygous from homozygous carriers, or C677T from A1298C. The CDC notes there is not enough evidence that A1298C alone significantly affects folate processing. Lumping all "MTHFR mutation" carriers together inflates the affected population dramatically.
  • Mechanistic inversion: MTHFR acts downstream of the point where folic acid enters folate metabolism and constrains folate from food in the same way. Presenting the variant as a folic acid specific blockage misstates the biochemistry.
  • Unsupported causal inference: "Put this nutrient into your body, and it elevates catecholamines... if you have ADD or ADHD, this is like gasoline on a fire." Science Feedback found no evidence that MTHFR variants interact with folic acid to cause ADHD, and no evidence was presented for the claim. An umbrella review instead reported that maternal folic acid supplementation may reduce ADHD risk in offspring.
  • Naturalistic framing as evidence: "made in a laboratory" is treated as a reason to doubt necessity. The efficacy question is settled by trial data, not by origin. The MRC randomised trial showed a 72 percent reduction in NTD recurrence using folic acid.
  • Care substitution risk: the transcript tells pregnant viewers to take methylfolate "not folic acid." CDC genetics experts state folic acid is the only form of folate shown to help prevent neural tube defects. The recommended substitute lacks the outcome evidence that the recommended intervention has.
  • Non-sequitur insertion: the postpartum depression sentence is followed by "Because if you have the gene mutation MTHFR," implying the MTHFR point explains the postpartum depression point. The two are unconnected.
What is uncertain
  • Whether specific subgroups, for example 677TT homozygotes with documented high homocysteine or existing folate deficiency, derive measurable additional benefit from 5-MTHF over folic acid. MedlinePlus notes a provider may recommend methylfolate in the homocysteine context. This is an individualised clinical question, not a population rule.
  • The clinical significance of unmetabolised folic acid in blood at high supplemental doses remains an active research area, with the literature not settled.
  • Whether any natural folic acid, as distinct from reduced folates, occurs in trace amounts in foods. Sources describe folic acid as the synthetic form while also noting Mitchell first isolated folic acid from spinach in 1941, which leaves the absolute "does not exist in nature" framing imprecise rather than clearly resolvable from the sources retrieved.
  • The postpartum depression and pregnancy hormone assertion was not investigated.
Evidence summary

The central claim is directly contradicted by the responsible public-health authority. The CDC states that people with an MTHFR gene variant can process all types of folate, including folic acid, that getting 400 mcg of folic acid daily helps prevent neural tube defects, and that folic acid intake matters more than MTHFR genotype for determining blood folate levels. The CDC further states that when getting the same amount of folic acid, people with the MTHFR 677 TT genotype have average blood folate only slightly lower, about 16 percent lower, than people with the CC genotype, and that studies show 400 mcg of folic acid daily increases blood folate levels regardless of MTHFR genotype. The CDC also says there is not enough evidence that the MTHFR A1298C variant alone significantly affects folate processing, and that common variants such as C677T are not a reason to avoid folic acid. A 16 percent average reduction in blood folate is a measurable efficiency difference, not an inability to process. A systematic review and meta-analysis in the American Journal of Clinical Nutrition found a consistent percentage difference in serum/plasma and red blood cell folate concentrations across MTHFR C677T genotypes. On the pregnancy recommendation specifically, CDC genetics experts state that folic acid is the only form of folate shown to help prevent neural tube defects, and that getting 400 micrograms of folic acid each day helps prevent neural tube defects even for women with the MTHFR C677T variant. The Cleveland Clinic similarly states that folic acid supplements before and during pregnancy can help prevent neural tube defects even in people with MTHFR variants, and that special types of folate are not needed. MedlinePlus notes that even if you have the MTHFR gene variant, the CDC recommends folic acid supplements for everyone who may become pregnant, while also noting that a provider may recommend methylfolate for lowering homocysteine since the body may use that form more easily. The underlying efficacy evidence is randomised. The 1991 MRC Vitamin Study randomised controlled trial in 1817 women at high risk because of a previous affected pregnancy demonstrated a 72 percent reduction in neural tube defect recurrence in the folic acid group. No comparable trial evidence exists for methylfolate preventing neural tube defects. The mechanistic framing in the post is also inverted. MTHFR acts downstream of the step that converts folic acid into the active folate pool, and it affects dietary folate and supplemental folic acid alike. Methyltetrahydrofolate is the MTHFR product and does not require reduction by DHFR to enter one-carbon folate metabolism, meaning the enzyme limited by MTHFR variants sits after the folic acid entry step, not at it. A reduced-activity MTHFR enzyme therefore limits conversion of folate from any source, which is why "MTHFR means you cannot process folic acid" does not follow. The ADHD and catecholamine assertion has been reviewed before. Science Feedback concluded there is no evidence that MTHFR gene variants interact with dietary folic acid to cause ADHD or that excess folic acid causes ADHD, and that Brecka presented no evidence for the claim. That review also noted that folic acid is water soluble and excess is excreted in urine. If anything, the directional evidence runs the other way: an umbrella review of systematic reviews and meta-analyses concluded that maternal folic acid supplementation may reduce the risk of ASD, ADHD and behavioural problems in offspring, though the authors frame this as a potential rather than established protective role.

Complete reasoning
The specific proposition, that people with the MTHFR gene variant cannot process folic acid, is directly contradicted by the CDC, which states in plain terms that people with an MTHFR variant can process all types of folate including folic acid, and quantifies the actual difference as roughly 16 percent lower average blood folate in the most affected genotype. This is a reduced-efficiency finding presented as a total metabolic blockage. A meta-analysis of genotype and blood folate, randomised trial evidence for folic acid in neural tube defect prevention, and the absence of equivalent outcome evidence for methylfolate all point the same way. The verdict is "false" rather than "misleading" because the operative word in the claim, "cannot," is the thing the evidence refutes, not merely an overstatement around a true core.
Use this case

The reply is formatted for pasting into the thread where the claim is circulating.

Ask this case

Answers come only from the case file above; nothing is added.

Does having the MTHFR gene mutation mean you can't process folic acid?

No. The CDC states that people with an MTHFR gene variant can process all types of folate, including folic acid. The variant reduces processing efficiency somewhat, but it does not cause a total inability.

How much does the MTHFR variant actually affect folate levels?

People with the common TT genotype have average blood folate about 16 percent lower than people without the variant, according to the CDC. That is a measurable efficiency difference, not a complete block.

Should people with MTHFR take methylfolate instead of folic acid during pregnancy?

The case file says folic acid is the only form of folate shown in a randomised trial to prevent neural tube defects, including a 72 percent reduction in recurrence. There is no comparable trial evidence for methylfolate, and the CDC recommends folic acid even for people with the MTHFR C677T variant.

Does folic acid make ADHD worse in people with MTHFR?

No evidence supports this. A prior review found no evidence that MTHFR variants interact with folic acid to cause ADHD, and a separate review found maternal folic acid supplementation may actually reduce ADHD risk in offspring.

Is it relevant that folic acid is made in a laboratory?

Folic acid is indeed synthetic and was first made in the 1940s, but the case file notes this fact does not undermine its effectiveness, which has been established through randomised trials.

Similar cases on record

False: People who carry a common variant in the MTHFR gene are unable to metabolise folic acid, a… | TrueSeeker